Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 3b study of dapagliflozin and saxagliptin in type 2 diabetes
MOH_2019-10-07_007157Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin and saxagliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by AstraZeneca. Started Sep 2019; status: active, not recruiting.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2019-10-07_007157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-07_007157.